66684-62-6

Basic information

• Product Name: 1,3-DIFLUORO-5-METHOXY-2-NITRO-BENZENE
• Synonyms: 3-difluoro-5-Methoxy-2-nitrobenzene;Benzene,1,3-difluoro-5-Methoxy-2-nitro-;3,5-Difluoro-4-nitroanisole【2,6-Difluoro-4-methoxy-1-nitrobenzene】;4-Nitro-3,5-difluoroanisole
• CAS NO: 66684-62-6
• Molecular Formula: C₇H₅F₂NO₃
• Molecular Weight: 189.12
• Mol File: 66684-62-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 255.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.414±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1,3-DIFLUORO-5-METHOXY-2-NITRO-BENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DIFLUORO-5-METHOXY-2-NITRO-BENZENE(66684-62-6)
• EPA Substance Registry System: 1,3-DIFLUORO-5-METHOXY-2-NITRO-BENZENE(66684-62-6)

Safety Data

• Hazardous Substances Data: 66684-62-6(Hazardous Substances Data)

Usage

General Description

1,3-Difluoro-5-methoxy-2-nitro-benzene is a chemical compound with the molecular formula C7H5F2NO3. It is a yellow crystalline solid with a molecular weight of 189.11 g/mol. This chemical is used in the synthesis of various pharmaceuticals and agrochemicals due to its versatile properties and reactivity. It is also commonly used as an intermediate in the production of dyes, pigments, and other fine chemicals. However, it is important to handle this compound with caution, as it is considered to be toxic and may cause irritation to the eyes, skin, and respiratory system. Additionally, it may have harmful effects on aquatic life and the environment if not properly managed.

Upstream product

• 315-14-0 1,3,5-trifluoro-2-nitrobenzene 
• 124-41-4 sodium methylate 
• 372-38-3 1,3,5-trifluorobenzene 
• 147808-41-1 4-hydroxy-2,6-difluoronitrobenzene 
• 74-88-4 methyl iodide 
• 2713-34-0 3,5-difluorophenol 

Downstream Products

• 151414-47-0 2,6-difluoro-4-methoxybenzenamine 
• 151414-42-5 2,6-difluoro-4-hydroxyacetanilide 
• 151414-48-1 2,6-difluoro-4-methoxyacetanilide 
• 932373-65-4 1,1-dimethylethyl 4-[(2-nitro-3-fluoro-5-methoxyphenyl)amino]-piperidinecarboxylate 
• 1226805-35-1 2-bromo-1-(3-fluoro-5-methoxy-2-nitrophenyl)-4-methyl-1H-imidazole 
• 1226803-65-1 6-fluoro-8-methoxy-1-(2-methoxyphenyl)-3-methylimidazo[5,1-c][1,2,4]benzotriazine 

Relevant articles and documents

HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS

The present invention relates to a compound of the following formula (I), or a salt, solvate, tautomer, enantiomer, diastereoisomer or racemic mixture thereof: as well as its use as a drug, notably in the treatment of hepatitis C, its preparation process, and the pharmaceutical compositions containing such a compound.

Highly potent, selective, and orally active phosphodiesterase 10A inhibitors

The identification of highly potent and orally active phenylpyrazines for the inhibition of PDE10A is reported. The new analogues exhibit subnanomolar potency for PDE10A, demonstrate high selectivity against all other members of the PDE family, and show desired druglike properties. Employing structure-based drug design approaches, we methodically explored two key regions of the binding pocket of the PDE10A enzyme to alter the planarity of the parent compound 1 and optimize its affinity for PDE10A. Bulky substituents at the C9 position led to elimination of the mutagenicity of 1, while a crucial hydrogen bond interaction with Glu716 markedly enhanced its potency and selectivity. A systematic assessment of the ADME and PK properties of the new analogues led to druglike development candidates. One of the more potent compounds, 96, displayed an IC50 for PDE10A of 0.7 nM and was active in predictive antipsychotic animal models.

ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10

The invention relates to imidazo[1,5-a]pyrazine derivatives, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.